Here, we determined that treatment with an AMPK agonist reduced the inflammatory response in hypoxia- or TNF-α-induced RA FLSs and ameliorated the severity of arthritis in rats with CIA, suggesting that AMPK is also a viable novel target for the treatment of RA. This evidence concerns the gene PRKAB1 and rheumatoid arthritis.